RecruitingNCT07390240
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia (HPP) in Children and Adults in Russia
Sponsor
AstraZeneca
Enrollment
55 participants
Start Date
Dec 29, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The effect of monoallelic variants in the ALPL gene on the natural course of hypophosphatasia (HPP) in children and adults in Russia (ATLANTIS)
Eligibility
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with hypophosphatasia. The study is currently recruiting participants at 4 locations.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07390240
Related Trials
Natural History Study of Patients With Hypophosphatasia (HPP)
NCT022376251 location
A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT0523456712 locations
Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
NCT0559653911 locations
United States Hypophosphatasia Molecular Research Center
NCT050626291 location
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT017931682 locations